Management of comorbid patients with chronic kidney disease and decline in renal function: a case report

Management of comorbid patients with chronic kidney disease and decline in renal function: a case report

Chronic kidney disease is one of the most important diseases in comorbid patients with cardiovascular disease. To reduce the risk of cardiovascular and renal complications, such patients should receive renin-angiotensin system inhibitors, statins and sodiumglucose cotransporter 2 inhibitors. However...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. I. Listratov, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2024-10-01
Series:	Российский кардиологический журнал
Subjects:	case report atrial fibrillation chronic kidney disease sodium-glucose cotransporter 2 inhibitors nephroprotective therapy
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/5790
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Nephroprotective and anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: real-world data
by: A. I. Listratov, et al.
Published: (2024-10-01)

Acute kidney injury as a risk factor for atrial fibrillation after coronary artery bypass grafting — effects of sodium-glucose cotransporter-2 inhibitors
by: L. V. Kremneva, et al.
Published: (2023-12-01)

Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01)

Mechanisms of acute renal injury caused by SGLT-2 inhibitor in patients with diabetes mellitus
by: Gong Yan, et al.
Published: (2021-01-01)

Progress in studies on renal effects and molecular mechanism of SGLT-2 inhibitors
by: XING Bei, et al.
Published: (2020-01-01)

Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients
by: Lucie Maigret, et al.
Published: (2025-03-01)

The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
by: M. Yu. Kolesnyk, et al.
Published: (2024-03-01)

Euglycemic diabetic ketoacidosis associated metabolic encephalopathy caused by dapagliflozin: a rare case report
by: Lulu Chu, et al.
Published: (2025-01-01)

Reverse myocardial remodeling according to cardiac magnetic resonance imaging in patients with heart failure and atrial fibrillation receiving dapagliflozin
by: K. M. Saipudinova, et al.
Published: (2024-10-01)

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01)

Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review
by: A. A. Kuzmenko, et al.
Published: (2022-10-01)

SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
by: Vladimir V Salukhov, et al.
Published: (2021-01-01)

New Possibilities in Quantitative Assessment of Albuminuria in Patients with Atrial Fibrillation and Chronic Kidney Disease
by: A. A. Sokolova, et al.
Published: (2021-07-01)

Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study
by: Jeong-Hoon Lim, et al.
Published: (2024-08-01)

Association of sodium-glucose cotransporter-2 inhibitor use and mortality in patients with endometrial cancer: a retrospective cohort study
by: Min Wang, et al.
Published: (2025-07-01)

Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis
by: Sadia Bari, et al.
Published: (2025-06-01)

Real‐world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study
by: Umut Kocabas, et al.
Published: (2025-02-01)

Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation
by: Lisa M. Raven, MBBS, FRACP, et al.
Published: (2025-05-01)

Factors influencing early renal function changes after SGLT2 inhibitors use and its long-term prognosis: a real-world retrospective study
by: Bing Xie, et al.
Published: (2025-12-01)

Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
by: E. R. Radkevich, et al.
Published: (2025-05-01)

The preventive effect of sodium-glucose co-transporter-2 inhibitors on atrial fibrillation and atrial flutter in patients with chronic kidney disease: a meta-analysis
by: Qian Yang, et al.
Published: (2025-05-01)

Induction of proximal tubular proliferation and lengthening in response to sodium glucose linked cotransporter‐2 inhibition in experimental rats
by: Ellen Wu, et al.
Published: (2025-07-01)

Budget Impact and Cost–Benefit Analyses of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in Thailand
by: Arunmanakul P, et al.
Published: (2025-02-01)

Perioperative euglycemic DKA: The YIN and YANG of sodium-glucose cotransporter 2 inhibitors
by: Shilpushp Bhosale, et al.
Published: (2025-01-01)

SGLT2 inhibitor administration to two patients with diabetes mellitus with ascites due to cirrhosis
by: Koji Nagayama, et al.
Published: (2025-07-01)

Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy
by: D. A. Napalkov, et al.
Published: (2019-09-01)

Prevalence, outcomes, costs, and treatments of a contemporary population with chronic kidney disease in Norway: a nationwide observational study
by: Trond Geir Jenssen, et al.
Published: (2025-07-01)

Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
by: Tarunveer S. Ahluwalia, et al.
Published: (2024-02-01)

Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers
by: Sul A. Lee, et al.
Published: (2024-06-01)

Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial
by: Ju-Hyun An, et al.
Published: (2025-08-01)

Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
by: Miloud Cherbi, et al.
Published: (2025-04-01)

Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study
by: Sangmo Hong, et al.
Published: (2025-07-01)

Possibilities of nephroprotection in a comorbid patient with arterial hypertension
by: A. S. Skotnikov, et al.
Published: (2021-06-01)

Refractory Arterial Hypertension: Features of Neurohormonal and Water-salt Imbalanceand Approaches to Antihypertensive Drug Therapy
by: O. B. Kuzmin, et al.
Published: (2022-09-01)

Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis
by: Peipei Li, et al.
Published: (2025-07-01)

Targeting ion channel networks in diabetic kidney disease: from molecular crosstalk to precision therapeutics and clinical innovation
by: Wenfeng Wang, et al.
Published: (2025-06-01)

Case Report: The long-term effects of the empagliflozin therapy on glycemia and renal function in a patient with Rabson-Mendenhall syndrome caused by two heterozygous variants in INSR gene
by: Joanna Chrzanowska, et al.
Published: (2025-04-01)

Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease
by: I. S. Daabul, et al.
Published: (2016-11-01)

Sodium–glucose cotransporter 2 inhibitors ameliorate glutathione cysteine ligase modifier-mediated oxidative stress and subsequent ferroptosis in proximal tubules of diabetic kidney disease
by: Yi-Chun Tsai, et al.
Published: (2025-12-01)

Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
by: K. Tobe, et al.
Published: (2021-07-01)